News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III                   Maria Platsis
Executive Vice President                Senior Director of Corporate Development
Chief Administrative Officer            and Investor Relations
(609) 936-2481                          (609) 936-2333
jhenneman@Integra-LS.com                mplatsis@Integra-LS.com


               Integra LifeSciences Announces Agreement to Acquire
                Radionics Division of Tyco Healthcare Group, L.P.


Plainsboro, New Jersey / September 7, 2005 / -- Integra LifeSciences Holdings
Corporation (NASDAQ: IART) announced today that it has agreed to acquire the
assets of the Radionics Division of Tyco Healthcare Group, L.P. for $80 million
in cash, subject to certain adjustments.


Radionics, based in Burlington, Massachusetts, is a leader in the design,
manufacture and sale of advanced minimally-invasive medical instruments in the
fields of neurosurgery and radiation therapy. Radionic's products include the
CUSA EXcel(TM) ultrasonic surgical aspiration system, the CRW(TM) stereotactic
system, the XKnife(TM) stereotactic radiosurgery system, and the OmniSight(TM)
EXcel image guided surgery system.


The Radionics business generated revenues of $62.2 million and pre-tax income of
$13.4 million for the year ending September 30, 2004, the most recent audited
period. Integra will acquire the Radionics facility in Burlington Massachusetts,
which employs approximately 135 employees, and enter into transitional supply
and distribution agreements with Tyco Healthcare for products currently
manufactured at Tyco facilities not included in the transaction.


The transaction offers a number of strategic benefits to Integra LifeSciences:

o        Increases its global neurosurgery product offering with the addition of
         an ultrasonic surgical aspirator product line, including handpiece,
         tip, and energy delivery designs utilizing magnetostrictive technology.

o        Positions the company to offer new stereotactic surgery products by
         combining its existing Mayfield(R) and Budde head-holding and
         retraction products with Radionic's CRW stereotactic head frame.

o        Secures entry into the radiosurgery/radiotherapy and image-guided
         surgery device business.

o        Adds to its manufacturing and R&D expertise in electronics,
         ultrasonics, and software.

o        Enhances the efficiencies of its global infrastructure and distribution
         network through economies of scale and cost synergies.



"This acquisition represents an ideal strategic fit for Integra LifeSciences. It
will expand our revenue base by approximately 15 percent and will enhance our
cash flow and profitability," said Stuart M. Essig, Integra's President and
Chief Executive Officer. "It will also increase our international business
significantly as approximately 45 percent of Radionics' business is outside of
the United States."


The CUSA EXcel(TM) ultrasonic surgical aspiration system is a well-recognized
device used in the selective removal of soft tissue in surgical procedures. The
Radionics products are primarily utilized by neurosurgeons in the diagnosis and
treatment of cancer and in the treatment of movement disorders. Neurosurgeons
use the CRW(TM) stereotactic system, which allows for the positioning of fine
instruments in the brain with submillimeter accuracy, for minimally invasive
brain biopsies, stereotactic craniotomies, and the placement of radiofrequency
probes or stimulating electrodes for the treatment of neurological disorders.
The XKnife(TM) system is used in the non-invasive treatment of intracranial
brain lesions, and the OmniSight(TM) EXcel system provides neurosurgeons and
orthopedic surgeons with enhanced three-dimensional visualization of critical
anatomy and the ability to perform less invasive surgical procedures.


"The acquisition of Radionics will strengthen Integra's product offering in
neurosurgery," said Stuart M. Essig, Integra's President and Chief Executive
Officer. "The Radionics products will provide an exceptional compliment to the
portfolio of products already offered by Integra NeuroSciences. We have great
respect for the Radionics team members who have brought so many outstanding
technologies to the neurosurgery device market," Essig added.


Tyco Healthcare sells the Radionics products in over 75 countries, using a
network of independent distributors in the United States and both independent
distributors and Tyco Healthcare affiliates internationally. Although Radionics
currently sells directly through many Tyco affiliates internationally, after
closing Integra is likely to use distributors in many of these markets. As a
result, under Integra management, Radionics' reported revenue and pre-tax income
(on a pro forma basis) is likely to be reduced by approximately 20% from the
2004 reported levels, prior to any impact associated with purchase accounting
related to the transaction.


Upon the closing of the transaction Integra expects to provide more detailed
guidance regarding the financial aspects of the transaction and its expected
impact on Integra's future financial results.


Completion of the transaction is subject to customary closing conditions,
regulatory approvals and expiration of the requisite waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act, as amended.


Integra LifeSciences Holdings Corporation is a diversified medical technology
company that develops, manufactures, and markets medical devices for use in a
variety of applications. The primary applications for our products are
neuro-trauma and neurosurgery, reconstructive surgery and general surgery.
Integra is a leader in applying the principles of biotechnology to medical
devices that improve patients' quality of life. Our corporate headquarters are
in Plainsboro, New Jersey, and we have manufacturing and research facilities
located throughout the world. We have approximately 1,300 employees. Please
visit our website at (http://www.Integra-LS.com).


This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning expectations for this
newly acquired business and the expected impact of this acquisition on Integra's
future financial results. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from
predicted or expected results. Among other things, Integra's ability to
successfully integrate the Radionics product lines into its operations could
affect the impact of this acquisition on Integra's future financial results. In
addition, the economic, competitive, governmental, technological and other
factors identified under the heading "Factors That May Affect Our Future
Performance" included in the Business section of Integra's Annual Report on Form
10-K for the year ended December 31, 2004 and information contained in
subsequent filings with the Securities and Exchange Commission could affect
actual results.



"Mayfield" is a registered trademark of SM USA, Inc., a wholly owned subsidiary
of Schaerer Mayfield USA, Inc.


Source: Integra LifeSciences Holdings Corporation